3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Dermatologic
1
Conditions
Multiple Myeloma
2
Melanoma
2
Endometrial Neoplasms
2
Uterine Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
1
Neoplasms
1
Mouth Neoplasms
1
Lung Neoplasms
1
Laryngeal Diseases
1
Hodgkin Disease
1
Hepatoblastoma
1
Head and Neck Neoplasms
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
pembrolizumab
37
Carboplatin
26
Radiotherapy
23
Cisplatin
19
Paclitaxel
18
Erlotinib Hydrochloride
18
Docetaxel
15
Gemcitabine
14
Pemetrexed
13
Etoposide
12
osimertinib
11
Nivolumab
11
durvalumab
9
atezolizumab
9
Radiosurgery
8
Magnetic Resonance Spectroscopy
8
Cetuximab
7
Specimen Handling
6
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
Taxes
5
Immunoglobulin G
5
Gefitinib
5
Biopsy
5
Bevacizumab
5
fludarabine
4
Radiation
4
Ipilimumab
4
Disulfides
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lung Neoplasms
×
dostarlimab
×
Clear all
NCT05060432
2024-06-21
TIG-006
iTeos Therapeutics
Phase 1/2
Active not recruiting
153 enrolled